Who is sponsoring NCT03298594?

NCT03298594 is sponsored by University Hospital, Geneva.

What drugs are being tested in NCT03298594?

Interventions in NCT03298594: specific cervicograph.

What condition does NCT03298594 study?

NCT03298594 studies Attempted Vaginal Delivery After a Cesarean Section.

Is NCT03298594 still recruiting?

NCT03298594 is currently completed. Last updated 2 October 2017.

Last reviewed 2017-10-02 · How we verify

NCT03298594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Specific Cervicograph for Women Attempting at Vaginal Delivery After Cesarean Section

Completed NA Last updated 2 October 2017

What this trial tests

NA trial testing specific cervicograph in Attempted Vaginal Delivery After a Cesarean Section in 135 participants. Completed in 11 October 2016.

Timeline

26 February 2013

Primary endpoint
11 October 2016

11 October 2016

Quick facts

Lead sponsor	University Hospital, Geneva
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	135
Start date	26 February 2013
Primary completion	11 October 2016
Estimated completion	11 October 2016

Drugs / interventions tested

specific cervicograph

Conditions studied

Attempted Vaginal Delivery After a Cesarean Section — all drugs for Attempted Vaginal Delivery After a Cesarean Section →

Sponsor

University Hospital, Geneva

Who can join

Adults 18 to 50, female only, with Attempted Vaginal Delivery After a Cesarean Section. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to evaluate a specific cervicograph (the graph describing the cervical dilation, included in the partograph) for pregnant women with an history of cesarean section, to improve the management of labor for women attempting at a vaginal delivery (VBAC). Women will be randomly assigned to this specific cervicograph (including an action line 2 hours after the alert line), or to the normal cervicograph (no lines). The primary outcome is appropriate detection of dystocia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Geneva trials

Trials by the same sponsor.

NCT07506356 — Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors · recruiting
NCT07267624 — EARLY Antibiotics aDAptation in Severe Pneumonia(The EARLY ADAPT Study) · NA · not yet recruiting
NCT06710210 — Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventi · NA · not yet recruiting
NCT07173348 — Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea · NA · not yet recruiting
NCT07129655 — Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Ch · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03298594 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Geneva
Last refreshed: 2 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03298594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing